Finance

Lists
Why is AGIO down 3,10%?
Dive Deeper
AGIO:NASDAQ
Agios Pharmaceuticals Inc
28,76 $
-3,10%
(-0,92) 1D
28,76 $
0,00% (0,00)
After hours
Closed: 19 қар., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGIO...
Open
29,93 $
High
30,35 $
Low
28,71 $
Mkt. cap
1,72 млрд
Avg. vol.
1,18 млн
Volume
0,00
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
29,93 $
High
30,35 $
Low
28,71 $
Mkt. cap
1,72 млрд
Avg. vol.
1,18 млн
Volume
0,00
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
Adam Feldman | Substack
Adam Feldman | Substack
·
16 сағат бұрын
Inside the Federal Litigation of Five S&P 500 Giants
The Harvard Law School Forum on Corporate Governance
The Harvard Law School Forum on Corporate Governance
·
22 сағат бұрын
Board Practices and Composition in the Russell 3000 and S&P 500
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
SectorHealth Care
Industry-
Websiteagios.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGIO in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGIO in the last 3 months.
Highest
Current 28,76 $
62,00 $ (+115,58%)
Average
45,80 $ (+59,25%)
Lowest
32,00 $ (+11,27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Hold
Maintained
32,00 $
+11,3%
11/05/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
48,00 $
+66,9%
11/06/2026
Douglas Tsao
H.C. Wainwright
Buy
Maintained
62,00 $
+115,6%
11/06/2026
Gregory Renza
Truist Financial
Buy
Maintained
35,00 $
+21,7%
11/06/2026
Tessa Romero
J.P. Morgan
Hold
Maintained
-
-
10/31/2026
Samantha Semenkow
Citi
Buy
Maintained
52,00 $
+80,8%
10/28/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/03/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
55,00 $
+91,2%
07/30/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
32,00 $
+11,3%
07/21/2026
Andrew Berens
Leerink Partners
Buy
Maintained
-
-
07/07/2026
Last report
2026 ж. 05 қар.
Fiscal period
Q3 2026
-1,09 $ / -1,23 $
+11,38%beat
Revenue / Est. (USD)
55,38 млн / 51,60 млн
+7,33%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
2026 ж. қыр.
Revenue
19,97 млн
20,75 млн
44,74 млн
55,38 млн
Cost of goods sold
89,94 млн
82,47 млн
103,75 млн
76,01 млн
Cost of revenue
89,94 млн
82,47 млн
103,75 млн
76,01 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
51,61 млн
48,30 млн
51,55 млн
56,53 млн
Operating expense
51,61 млн
48,30 млн
51,55 млн
56,53 млн
Total operating expenses
141,54 млн
130,77 млн
155,30 млн
132,54 млн
Operating income
-121,58 млн
-110,02 млн
-110,55 млн
-77,16 млн
Other non operating income
113,00 м.
119,00 м.
119,00 м.
3,24 млн
EBT including unusual items
-109,06 млн
-99,11 млн
-100,70 млн
-65,04 млн
EBT excluding unusual items
-109,06 млн
-99,11 млн
-100,70 млн
-65,04 млн
Income tax expense
-1,02 млн
-
-
-
Effective tax rate
0,93%
-
-
-
Other operating expenses
-
-
-
-
Net income
-108,04 млн
-99,11 млн
-100,70 млн
-65,04 млн
Net profit margin
-541,09%
-477,74%
-225,06%
-117,44%
Earnings per share
-1,85
-1,69
-1,69
-1,09
Interest and investment income
12,41 млн
10,80 млн
9,73 млн
8,88 млн
Interest expense
-
-
-
-
Net interest expenses
12,41 млн
10,80 млн
9,73 млн
8,88 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-120,31 млн
-108,66 млн
-109,20 млн
-75,71 млн
Gain or loss from assets sale
-299,00 м.
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google қолданбалары